CytoDyn Updates Time of Presentation at the H.C. Wainwright 27th Annual Global Investment Conference

Rhea-AI Summary

CytoDyn (OTCQB: CYDY), a clinical-stage biotech company developing leronlimab, has announced a schedule change for its presentation at the H.C. Wainwright 27th Annual Global Investment Conference. The company's CFO, Robert E. Hoffman, will now present on Wednesday, September 10, 2025, at 9:00 AM EDT in New York City.

The presentation will showcase CytoDyn's progress with leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor, which shows therapeutic potential across multiple indications. One-on-one meetings with management will be available throughout the conference, which runs from September 8-10, 2025.

News Market Reaction – CYDY

+2.56%

+2.56% Session close to close

In the Sep 4 session, CYDY gained 2.56%, reflecting a moderate positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

VANCOUVER, Washington, Sept. 04, 2025 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTCQB: CYDY) ("CytoDyn" or the "Company"), a clinical-stage biotechnology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, today announced a change of time for management’s live presentation at the H.C. Wainwright 27th Annual Global Investment Conference, to Wednesday, September 10, at 9 a.m. EDT.

CytoDyn CFO, Robert E. Hoffman, will deliver a live company presentation and will be available for one-on-one meetings throughout the event, which is taking place September 8-10, 2025, in New York City.

Details of the presentation are now as follows:

Event: H.C. Wainwright 27th Annual Global Investment Conference

Date: September 10, 2025

Time: 9 a.m. EDT

Webcast: register here

About CytoDyn

CytoDyn is a clinical-stage biotechnology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders.

Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.

For more information, please visit www.cytodyn.com and follow us on LinkedIn.

Investor Relations

CytoDyn Inc.
ir@cytodyn.com

Media Contacts

Rob Haney, Ph.D., or Ignacio Guerrero-Ros, Ph.D.
Russo Partners, LLC
CytoDyn@russopartnersllc.com

FAQ

When is CytoDyn (CYDY) presenting at the H.C. Wainwright Conference 2025?

CytoDyn will present on Wednesday, September 10, 2025, at 9:00 AM EDT at the H.C. Wainwright Global Investment Conference in New York City.

Who will be presenting for CytoDyn at the H.C. Wainwright Conference?

Robert E. Hoffman, CytoDyn's CFO, will deliver the company presentation.

What is CytoDyn's main product in development?

CytoDyn is developing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications.

Will investors be able to meet with CytoDyn management at the conference?

Yes, management will be available for one-on-one meetings throughout the conference, which runs from September 8-10, 2025.